㎡ Independent
R&D Center
11,000㎡ Industrial Production Base (Phase I)
Projects under R&D
Clinical Trial Permissions
Bowei Bioscience

Bowei Bioscience


Shanghai Bovax
Chongqing Bovax
Shanghai Bovax Biotechnology Co., Ltd. (hereafter referred as to "Shanghai Bovax") ,  established in December 2012, is a National High-tech Enterprise specializing in the R&D of innovative recombinant protein vaccines and drugs.
Shanghai Bovax is located at Building 12, Lane 908, Ziping Road, Yigu Plus, International Medical Park, Shanghai, China. It has a 3000GMP-compliant independent R&D center for R&D, pilot-trial, non-clinical and clinical study of innovative drugs and vaccines. The major equipments and instruments were purchased from renowned global companies. Shanghai Bovax employs more than 80 R&D professionals, more than 50% of them have master's or higher degrees.
The company has obtained the qualification of Shanghai Bio Safety Level-2 Laboratory (BSL-2). It was the undertaking company of The Science and Technology Major Project for "Significant New Drugs Development" of the Ministry of Science and Technology of China during "The 13th Five-Year Plan", as well as "The Science and Technology Innovation Action Plan"of Shanghai.  

Chongqing Bovax  Biopharmaceutical Co., Ltd. (hereafter referred as to "Chongqing Bovax"), as the wholly-owned subsidiary of Shanghai Bovax Biotechnology Co., Ltd., is an innovative enterprise focusing on the R&D and industrialization of recombinant protein vaccines and drugs. It was established in Chongqing BioPark in 2016, and used for the industrialization of prophylactic recombinant protein vaccines. The construction of Chongqing Bovax has been completed and put into use.

Bovax  has mastered the international advanced genetic engineering recombinant Virus-Like Particles technology (VLPs technology), and has established multiple technology platforms with recombinant expression of VLPs in eukaryocyte systems as the core technology. These technology platforms have a wide range of applications in prophylactic vaccines and therapeutic drugs for cancers and infectious diseases, such as human papillomavirus (HPV) vaccine, hand-foot-and-mouth disease (HFMD) vaccine and Norovirus vaccine. Chongqing Bovax is in a leading position in the field of HPV vaccine research and development in China.  
Recombinant virus-like particles (VLPs) vaccine development technologyplatform
Learn more
Therapeutic protein drug technology development platform
New Biological Products Project Application Service Platform
Recombinant Virus-Like Particles(vlps) Vaccine Development Technology  Platform
New Biological Products Application Service Platform
Let technological progress bring true benefits to the people.
Article display 3448

Article display 3448


Company News
Industry News
Recently, the Shanghai Municipal Commission of Economy and Informatization published the list of Shanghai Innovative Small and Medium-Sized enterprises in 2023 (the fourth releasing), where our compan
Currently, the 15-Valent Recombinant Human Papillomavirus Vaccine (Hansenula polymorpha), jointly developed by Shanghai Bovax Biotechnology Co., Ltd. and its subsidiary company Chongqing Bo...
Currently, Bovax has initiated the Phase I clinical trial for the Recombinant Enterovirus 71 Vaccine (Hansenula polymorpha), which developed independently by Bovax. The first subject has be...
Since November, a new round of the Covid-19 epidemic had been spreading in Chongqing. In response, Chongqing Bovax has implemented closed-loop management. Before conducting closed-loop management, ...
The report is released ahead of the 2024 Seventy-seventh World Health Assembly, which runs 27 May – 1 June 2024. WHO's revised Programme Budget for 2022–2023 was US$ 6726.1 million, incorporating l...